Epithelial-mesenchymal transition (EMT) is a fundamental cellular process in epithelial tissue development, and can be reactivated in cancer contributing to tumor invasiveness and metastasis. The cytokine transforming growth factor-β (TGFβ) is a key inducer of EMT, but the mechanisms that regulate TGFβ-induced EMT remain incompletely understood. Here, we report that knockdown of the ubiquitin ligase Smurf2 promotes the ability of TGFβ to induce EMT in a three-dimensional cell culture model of NMuMG mammary epithelial cells. In other studies, we identify Smurf2 as a target of the small ubiquitin like modifier (SUMO) pathway. We find that the SUMO-E2 conjugating enzyme Ubc9 and the SUMO E3 ligase PIAS3 associate with Smurf2 and promote its sumoylation at the distinct sites of Lysines 26 and 369. The sumoylation of Smurf2 enhances its ability to induce the degradation of the TGFβ receptor and thereby suppresses EMT in NMuMG cells. Collectively, our data reveal that Smurf2 acts in a sumoylationregulated manner to suppress TGFβ-induced EMT. These findings have significant implications for our understanding of epithelial tissue development and cancer. Cell Death and Differentiation (2016) 23, 876-888; doi:10.1038/cdd.2015; published online 18 December 2015
Epithelial-mesenchymal transition (EMT) is an essential process in epithelial tissue morphogenesis in the developing organism and contributes to postnatal events including mammary postnatal gland development as well as wound healing.
1,2 Importantly, EMT can be reactivated during cancer and may contribute to tumor invasiveness. 3 Epithelial cells undergoing EMT change phenotypically from cuboidal to fibroblastic morphology, lose epithelial markers including E-cadherin, gain mesenchymal markers, and display increased cell motility and invasiveness. 4, 5 The secreted factor transforming growth factor-β (TGFβ) has emerged as a potent inducer of EMT with key roles in development and cancer. 6 Thus, there has been interest in the mechanisms that mediate TGFβ-induced EMT.
Smurf2 (Smad (Sma and mad) ubiquitination regulatory factor-2) is a HECT (for homology to E6 carboxy terminus domain)-containing E3 ubiquitin ligase that specifies substrates for ubiquitination and degradation by the proteasome. 7, 8 Smurf2 regulates key biological processes during development and homeostasis including cell polarity, cell cycle, and senescence in an E3 ligase-dependent or -independent manner. [9] [10] [11] [12] [13] [14] [15] The biological functions of Smurf2 occur via regulation of signaling pathways including the TGFβ-Smad signaling pathway. [16] [17] [18] [19] [20] [21] [22] [23] However, the role of Smurf2 in TGFβ-induced EMT has remained to be determined.
Sumoylation refers to the covalent attachment of the small ubiquitin-like modifier (SUMO), to protein substrates by the SUMO pathway. 24 SUMO is linked to its substrates by an iso-peptide bond between C-terminal carboxyl group of SUMO and ε-amino group of a lysine residue in the substrate. The SUMO E2 conjugating enzyme Ubc9, the second enzyme of a three-step catalytic cascade, covalently forms a thioester bond with SUMO, and selectively associates with and promotes the transfer of the SUMO to substrates. 25 SUMO E3 ligases, for example, the protein inhibitors of activated STATs (PIAS family proteins), form complexes with both the substrate and Ubc9, thereby facilitating the transfer of SUMO from E2 to the substrate. Sumoylation is a reversible process owing to the activity of sentrin-specific proteases (SENPs) that desumoylate SUMO protein substrates. 25, 26 Because sumoylation has major functional consequences for its target substrates, there has been a great deal of interest in identifying novel SUMO substrates.
In this study, we have uncovered a novel sumoylationdependent function for the ubiquitin ligase Smurf2 in TGFβ-induced EMT. Knockdown and gain-of-function analyses reveal that Smurf2 suppresses TGFβ-induced EMT in NMuMG mammary epithelial cells, a widely used cellular model system of EMT. In other experiments, we show that the SUMO E2 conjugating enzyme Ubc9 and the SUMO E3 ligase PIAS3 associate with Smurf2 and promote its sumoylation at Lysines 26 and 369 in distinct cell types. The sumoylation of Smurf2 enhances its ability to trigger the degradation of the TGFβ receptor TβRI and thereby suppresses EMT. Taken together, our findings unveil an intimate new link between sumoylated Smurf2 and the regulation of EMT. Our studies point to an important regulatory role for sumoylation of Smurf2 in tissue morphogenesis and cancer progression.
Results

Smurf2 suppresses EMT.
EMT is a fundamental process in development, with increasing evidence suggesting that it plays key roles in cancer cell invasion and metastasis. [27] [28] [29] TGFβ is a potent inducer of EMT in development and cancer, 3, 30 and the canonical Smad signaling pathway contributes to the ability of TGFβ to promote EMT. [31] [32] [33] The E3 ubiquitin ligase Smurf2 associates with members of the Smad family of signaling proteins and thereby regulates TGFβ-mediated responses. 34, 35 However, the role and regulation of Smurf2 in TGFβ-induced EMT has remained unexplored.
The nontransformed mammary NMuMG epithelial cells represent a well-established and suitable model to study EMT. 33, 36, 37 Growing evidence suggests that culturing epithelial cells in the context of an extracellular support system such as Matrigel provides a three-dimensional (3D) environment for cells resembling the stromal basement membrane under more 'physiological' conditions. [38] [39] [40] Accordingly, glandular-derived epithelial cells in a 3D matrix form acini with hollow centers similar to the morphology of these structures in vivo. Importantly, EMT disrupts the acinar morphology that manifests as filling of the hollow centers, outward invasiveness, and dysregulation of the abundance or localization of the epithelial marker protein E-cadherin. 38, [40] [41] [42] [43] To determine the role of Smurf2 in EMT, we induced the knockdown of Smurf2 by RNA interference (RNAi) in NMuMG cells using transient transfection. Short hairpin RNAs (shRNAs) targeted against two distinct regions within Smurf2, alone or together, robustly downregulated exogenous Smurf2 in 293T cells and NMuMG mammary epithelial cells (Supplementary Figures S1A and B) . Importantly, the two Smurf2 shRNAs, alone or together, also significantly reduced the abundance of endogenous Smurf2 in NMuMG cells (Figure 1a and Supplementary Figure S1C ). We next determined the effect of Smurf2 knockdown on the ability of TGFβ to induce EMT in NMuMG cells. As expected, NMuMG cells seeded as single cells in 3D cultures formed organized hollow acini, and exposure to TGFβ led to filling and disorganization of these multicellular structures (Figure 1b) . 40 In contrast, we found that Smurf2 knockdown by shRNA-1 and shRNA-2, separately or together, promoted filling of NMuMG cell-derived acini in the absence of TGFβ, and enhanced the ability of TGFβ to induce lumen filling and disorganization of NMuMG cell acini (Figure 1b and Supplementary Figure S1D) . In immunocytochemical analyses, E-cadherin localized to intercellular junctions in control cells (Figure 1c and data not shown), and TGFβ reduced the abundance or mislocalized E-cadherin, consistent with EMT induction. 40 Smurf2 knockdown by shRNA-1 and shRNA-2, individually or together, further enhanced the ability of TGFβ to downregulate E-cadherin expression (Figure 1c and data not shown). These data suggest that endogenous Smurf2 inhibits TGFβ-induced EMT in epithelial cells.
In complementary experiments, expression of Smurf2 in NMuMG cells blocked the ability of TGFβ to disrupt the acinar morphology and downregulate E-cadherin in the 3D NMuMG cell-derived structures (Figures 1d-f) . Importantly, expression of a rescue form of Smurf2 encoded by cDNA that is resistant to Smurf2 RNAi-1 ((Smurf2(r1)) or Smurf2 RNAi-2 (Smurf2(r2)), but not Smurf2 encoded by wild type cDNA, reversed the ability of Smurf2 knockdown by RNAi-1 or RNAi-2, respectively, to promote the filling of NMuMG-derived acini in the absence or presence of TGFβ (Figures 1g and h and Supplementary Figures S1E and F) . Expression of Smurf2(r1) or Smurf2(r2) also reversed the ability of Smurf2 knockdown to enhance the ability of TGFβ to reduce or mislocalize E-cadherin in NMuMG-derived acini (Supplementary Figures S1G and H) . Together, these data suggest that endogenous Smurf2 suppresses TGFβ-induced EMT in the nontransformed epithelial cells.
Smurf2 is a novel substrate of the SUMO pathway. The finding that Smurf2 suppresses TGFβ-induced EMT raised the question of how this novel function of Smurf2 is regulated in epithelial cells. Smurf2 has been suggested to be targeted by the ubiquitin-proteasome pathway. 44 However, we found no appreciable reduction in the abundance of Smurf2 in NMuMG cells undergoing TGFβ-induced EMT (Figure 1d) . We, therefore, asked whether Smurf2 function in EMT might be regulated by sumoylation. Sumoylation of target proteins has profound consequences on the functions of target proteins. A cascade of three enzymes, a SUMO E1 activating enzyme, the SUMO E2 conjugating enzyme Ubc9, and a SUMO E3 ligase, promote the covalent attachment of the protein SUMO with target proteins. On the other hand, members of the SENP family of desumoylases remove SUMO from protein substrates. 25, 26 The isopeptidase inhibitor N-ethylmaleimide (NEM) is included in lysis buffer to inhibit the SENP and preserve sumoylation of substrates. [45] [46] [47] Although free SUMO is ∼ 11 kDa in size, its conjugation adds an apparent molecular mass of ≥ 20 kDa to the molecular mass of the substrate in immunoblotting analyses. 25, 46, 48 To determine whether Smurf2 might be sumoylated, we subjected NMuMG cell lysates prepared in sodium dodecyl sulfate (SDS)-containing lysis buffer in the absence or presence of NEM to immunoprecipitation with the Smurf2 antibody followed by immunoblotting with the SUMO and Smurf2 antibodies. Typically, only a small fraction of sumoylated protein substrate may be detected. 25 Thus, in addition to assessing endogenous Smurf2 sumoylation in NMuMG cells (Figure 2a, lanes 1 and 2) , we included cells that express exogenous Smurf2 in these analyses (Figure 2a (Figure 2c ). To gain further evidence for Smurf2 sumoylation, we carried out in vivo sumoylation assays in 293T cells that are widely used in sumoylation analyses. 45 We expressed MYC-tagged Smurf2, HA-tagged SUMO, or both proteins together in 293T cells and subjected their lysates to immunoprecipitation with the MYC antibody followed by immunoblotting with the HA or MYC antibody. Expression of SUMO with Smurf2 led to the appearance of a 100-kDa as well as poly-sumoylated Smurf2 in an NEM-sensitive manner (Figure 2d) . Collectively, these shRNA-1 (Smurf2i-1), together with an expression plasmid encoding an RNAi-resistant MYC-tagged Smurf2 (Smurf2(r1)) or a Smurf2 encoded by WT cDNA or the corresponding plasmid control, or with the control plasmids, and treated as in (b). Expression of Smurf2(r1), but not WT Smurf2, reversed Smurf2i-1-induced NMuMG cell-derived acini filling in the absence or presence of TGFβ (ANOVA, ***Po0.001). Scale bar = 50 μm (b, c, e, f, and h). Arrows and arrowheads indicate intact and disrupted acini, respectively data suggest that Smurf2 is modified by the SUMO pathway in cells.
The SUMO E2 enzyme Ubc9 promotes sumoylation by association with its substrates. 25 In coimmunoprecipitation analyses, we found that Ubc9 forms a complex with Smurf2 in cells ( Figure 3a ). We next determined the effect of expression of wild-type Ubc9 or a SUMO-conjugating inactive Ubc9 mutant, in which the catalytic Cysteine 93 is replaced with serine (CS), 49, 50 on exogenous Smurf2 sumoylation in 293T cells. Expression of wild-type Ubc9, but not Ubc9 (CS), enhanced the sumoylation of exogenous Smurf2 in 293T cells (Figures 3b and c) . Expression of Ubc9 also led to robust sumoylation of endogenous Smurf2 in NMuMG cells (Supplementary Figure S2A) . Together, these data demonstrate that Ubc9 associates with and promotes the sumoylation of Smurf2.
We next determined the role of SUMO E3 ligases in Smurf2 sumoylation. PIAS represent the largest family of SUMO E3 ligases. 50, 51 We measured the effect of expression of the four PIAS family members PIAS1, PIAS2, PIAS3, or PIAS4 on Smurf2 sumoylation in 293T cells. 25, 45, 51 Among the PIAS proteins, PIAS3 enhanced Smurf2 sumoylation (Figures 3d and e and data not shown). In reciprocal coimmunoprecipitation studies, we found that Smurf2 and PIAS3 form a complex in cells (Figure 3f ). Importantly, we found that PIAS3 enhanced sumoylation of endogenous Smurf2 in NMuMG cells (Supplementary Figure S2B) .
Sumoylation is a dynamic and reversible process due to the action of the SUMO cleaving SENP family of isopeptidases. 25, 52 Employing in vivo sumoylation assays, we observed that expression of SENP1 or SENP2 but not SENP3 led to complete loss of the 100 kDa and Figure 3 The SUMO E2 enzyme Ubc9 and the SUMO E3 ligase PIAS3 promote and the SUMO isopeptidases SENP1/2 inhibit Smurf2 sumoylation. (a) Lysates of 293T cells expressing MYC-tagged Smurf2 and HA-tagged Ubc9 alone or together were subjected to Ubc9 immunoprecipitation (HA IP) followed by Smurf2 (MYC) and Ubc9 (HA) immunoblotting. Smurf2 protein abundance in the lysates was confirmed by Smurf2 immunoblotting (MYC IB). Immunoblotting for actin in lysates was used as loading control. LC, light chain. (b) NEM-treated lysates of 293T cells expressing MYC-tagged Smurf2, HA-tagged SUMO, WT Ubc9, or an E2 SUMO conjugating inactive Ubc9 in which Cysteine 93 is converted to serine (CS) were subjected to in vivo sumoylation assay as described in Figure 2d . Expression of MYC/Smurf2, mono/di HA/SUMO, or HA/Ubc9 was confirmed by immunoblotting with the MYC and HA antibodies. Actin immunoblotting was used as a loading control. Note SUMO is conjugated to protein substrates and can be detected as higher molecular species compared with unmodified substrate. Ubc9 promotes the sumoylation of Smurf2. *Indicates a nonspecific band. (c) The bar graph shows the proportion of sumoylated Smurf2 relative to unmodified Smurf2 in the absence and presence of WTor CS Ubc9 as expressed relative to proportion of Smurf2 sumoylation in the absence of Ubc9 (mean ± S.E.M., n = 4). (d) Lysates of 293T cells expressing MYC-tagged Smurf2 alone or together with Ubc9 and SUMO, alone or together with a low (+) and high (++) concentrations of the SUMO E3 ligase PIAS3 (FLAG-PIAS3), were subjected to Smurf2 sumoylation assay as described in Figure 2d (upper panel). Expression of FLAG-tagged PIAS3 was confirmed in cell lysates. Actin was used as a loading control. (e) The bar graph depicts the proportion of SUMO-conjugated Smurf2 in the absence or presence of PIAS3 expressed relative to the proportion of sumoylated Smurf2 in the absence of PIAS3 (mean ± S.E.M., n = 4). (f) Lysates of cells expressing FLAG-tagged PIAS3 and MYCtagged Smurf2, alone or together, were subjected to immunoprecipitation for Smurf2 (MYC IP) or PIAS3 (FLAG IP) followed by immunoblotting for PIAS3 (FLAG IB, first panel) or Smurf2 (MYC IB, sixth panel), respectively. Immunoprecipitation of Smurf2 (MYC IB, second panel) and PIAS3 (FLAG IB, seventh) was confirmed. Expression of Smurf2 (MYC IB) and PIAS3 (FLAG IB) in lysates was assessed by immunoblotting, with actin used as loading control. (g) Lysates of 293T cells expressing Ubc9 and SUMO alone or together with different combinations of MYC-tagged Smurf2, FLAG-tagged SENP1, or SENP2 were subjected to a Smurf2 sumoylation assay (upper panel). Expression of MYC-tagged Smurf2 was confirmed in cell lysates as described in (a). *Indicates a nonspecific band. (h) The bar graph shows the proportion of sumoylated Smurf2 normalized to unmodified Smurf2 and expressed relative to sumoylated Smurf2 in the absence of SENP1 or SENP2 coexpression (mean ± S.E.M., n = 4). (i) The SUMO E2 conjugating enzyme Ubc9 acts together with the SUMO E3 ligase PIAS3 to associate and promote the sumoylation of Smurf2 in cells. Significant difference **Po0.01 and ***Po0.001 (ANOVA or t-test)
higher-molecular-mass SUMO-immunoreactive bands in the Smurf2 immunoprecipitates (Figures 3g and h and data not shown), suggesting that SENP1 and SENP2 catalyze the desumoylation of Smurf2 in cells. Collectively, our results suggest that the SUMO E2 enzyme Ubc9 and the SUMO E3 ligase PIAS3 promote whereas the SUMO isopeptidases SENP1/2 inhibit the sumoylation of Smurf2 (see model in Figure 3i ).
We next mapped the lysine residues within Smurf2 that are covalently linked to SUMO. SUMO is conjugated to substrates at lysine residue residing in a consensus SUMO motif, ψKXD/E, where ψ is a large hydrophobic residue, K is a lysine residue, X denotes any amino acid, and E/D refer to glutamic acid or aspartic acid, respectively. Using the SUMOplot software (Abgent, San Diego, CA, USA) and SUMO sp2.0 (Guangzhou, China), we identified two specific lysine residues, K26 and K369, as putative consensus sites of sumoylation motifs that are conserved in human, mouse, and chicken Smurf2 (Figure 4a ). To test whether one or both lysine residues corresponding to residues 26 and 369 of human Smurf2 are sumoylated, we expressed in 293T cells human Smurf2 with either Lysine 26 (K26R) or 369 (K369R) or both residues (KdR) mutated to arginine. Mutation of Lysines 26 and 369, alone or together, reduced the level of Smurf2 sumoylation, suggesting that these lysines are major SUMO acceptor sites in Smurf2 (Figures 4b and c) . We also characterized the sumoylation sites in Smurf2 that was expressed as part of a Renilla fusion protein (Rluc-Smurf2) in 293T and NMuMG cells. Unmodified Rluc-Smurf2 had an apparent molecular mass of ∼ 125 kDa, and accordingly sumoylated Rluc-smurf2 was detected with an approximate molecular mass of 145 kDa in 293T and NMuMG cells (Supplementary Figures S3A and B) . Mutation of Lysines 26 and 369 abrogated sumoylated Rluc-Smurf2 in these cells (Supplementary Figures S3A and B) . Taken together, our results suggest that Lysines 26 and 369 are major SUMO acceptor sites in Smurf2 in different cell types.
Sumoylated Smurf2 suppresses TGFβ-induced EMT.
Next, we determined the role of sumoylation of Smurf2 in its ability to suppress EMT.
We compared the effect of wild-type Smurf2 (Smurf2WT) or a SUMO loss-of-function Smurf2 mutant in which Lysines 26 and 369 were replaced with arginine (Smurf2KdR) on TGFβ-induced disruption of morphogenesis of acini in 3D NMuMG cultures in the absence or presence of TGFβ (100 pM) for 10 days. Expression of Smurf2WT suppressed TGFβ-induced lumen filling and disorganization of NMuMG acini (Figures 1e and 5b) . In contrast, expression of Smurf2KdR failed to suppress TGFβ-induced lumen filling and disorganization of NMuMG acini (Figure 5b) . Rather, expression of Smurf2KdR enhanced lumen filling of NMuMG acini, thus phenocopying the effect of Smurf2 knockdown (Figures 1b and h and 5b and Supplementary Figures  S1D and F) . Accordingly, immunocytochemical analyses using the E-cadherin antibody showed that Smurf2WT blocked whereas Smurf2KdR promoted the ability of TGFβ to downregulate and disrupt the localization of E-cadherin (Figure 5c ). These data suggest that sumoylation is critical for the ability of Smurf2 to suppress TGFβ-induced EMT in 3D NMuMG-derived acini structures.
We next assessed the role of the TGFβ-Smad pathway in the ability of sumoylated Smurf2 to suppress EMT. TGFβ binds and assembles type I and II Ser/Thr kinase cell surface receptors into an active heteromeric complex, whereby the activated type I receptor kinase stimulates downstream signaling events and consequent responses including EMT. 53, 54 We compared the effect of blockade of the type I kinase receptor by the small molecule inhibitor, SB431542, on the ability of Smurf2 knockdown or the SUMO loss of function Smurf2 mutant (Smurf2KdR) to promote acini filling and disorganization (Figures 6a and b and Supplementary  Figures S4A and B) . As expected, incubation of the vectortransfected NMuMG cell-derived 3D multicellular organoids with the TGFβ receptor kinase inhibitor promoted acini formation and maintenance, and enhanced E-cadherin Figures S4A and B) . 40 Remarkably, the Smurf2 knockdown-or Smurf2KdR-induced acini filling and disorganization and loss or mislocalization of E-cadherin were reversed by blockade of the TGFβ Ser/Thr kinase receptors in the presence or absence of TGFβ (Figures 6a and b and Supplementary Figures S4A and B) , suggesting that TGFβ receptor-mediated signaling is a target for sumoylated Smurf2 to suppress EMT.
The signaling proteins Smad2 and Smad3 are major downstream mediators of TGFβ-induced responses including EMT. 55 Accordingly, knockdown of Smad2 or Smad3 suppressed, whereas expression of Smad2 or Smad3 promoted, the ability of TGFβ to induce EMT in the 3D NMuMG cellderived acini (Supplementary Figures S5A-D) . Importantly, we found that knockdown of Smad3 drastically suppressed the ability of Smurf2 knockdown or Smurf2KdR expression to induce acini filling and disorganization of NMuMG organoids in ) were analyzed for the adherens junction protein E-cadherin abundance and localization. Cells were identified by nuclear staining as described in Figure 1c .Scale bar = 50 μm (b and c). Arrows and arrowheads indicate intact and disrupted acini, respectively the absence or presence of TGFβ (Figures 7a and b) . In immunofluorescence analyses, Smad3 knockdown also suppressed the downregulation of E-cadherin and its mislocalization upon Smurf2 knockdown or expression of Smurf2KdR (Supplementary Figures S5E and F) . Taken together, these data suggest that sumoylated Smurf2 suppresses EMT via regulation of the TGFβ-Smad pathway.
Smurf2 promotes the ubiquitin-mediated degradation of the TGFβ type I receptor. 23, 35 To gain insight into the mechanisms by which sumoylated Smurf2 suppresses TGFβ-induced EMT, we compared the ability of Smurf2WT and Smurf2KdR to reduce the abundance of the TGFβ type I receptor (TβRI). As expected, Smurf2WT substantially reduced the abundance of TβRI in cells (Figure 8a ). In contrast, expression of Smurf2KdR failed to effectively reduce the levels of TβRI (Figure 8a ). The inability of Smurf2KdR to efficiently reduce the levels of the TβRI was not due to lack of association, as coimmunoprecipitation analyses demonstrated that Smurf2KdR interacts, similar to Smurf2WT, with activated TβRI (TβRI (TD); Figure 8b ), suggesting that sumoylation promotes the ability of Smurf2 to induce the degradation of TβRI. Smad7 and Smurf2 associate in a bipartite manner whereby Smad7's N-terminal domain (NTD) and PPXY motif interact with Smurf2's HECT and WW domains, respectively. In particular, the NTD-HECT association promotes the autoubiquitination activity of Smurf2 by recruiting E2s to Smurf2. 35, 44, 56 In control analyses, the KdR mutation had little or no effect on the association of Smurf2 with Smad7 or on Smad7-induced downregulation of Smurf2 (Figures 8c and d) . Notably, Lysine 369 is located N-terminal to the HECT domain (Figure 8e ). Together, these observations suggest that the KdR mutation does not have nonspecific effects on the interaction of Smurf2 with cognate E2 or on Smurf2 autoregulation. The C2 domain of Smurf2 associates with the HECT domain to inhibit Smurf2 autoregulation. 44 Lysine 26 resides in the N-terminal region of the C2 domain (Figure 8e ). In additional control analyses, conversion of Lysine 26 or 369 to arginine failed to reduce the interaction of the C2 and HECT domains (Figure 8f) , suggesting that the KdR mutation does not have nonspecific effects on intramolecular interaction of Smurf2 (Figure 8f ). The C2 domain regulates Smurf2 localization in cells. 56, 57 In control immunofluorescence analyses, Smurf2WT and Smurf2KdR showed similar subcellular localization in NMuMG cells (Figure 8g ). Taken together, our data support the idea that sumoylation of Smurf2 enhances its ability to promote TGFβ receptor degradation and thereby suppresses EMT.
Collectively, we have identified a novel PIAS3-Smurf2 sumoylation link that suppresses TGFβ-induced EMT (see model in Figure 8h ). , and Smad7, together with a vector control or a plasmid encoding MYC-tagged WT Smurf2 (Smurf2WT) or Smurf2KdR, were subjected to TβRI (α-HA), TβRII (α-TβRII), Smurf2 (α-MYC), and actin immunoblotting, the latter serving as the loading control. Left, representative immunoblot from an experiment that was repeated five independent times. Right, mean ( ± S.E.M., n = 5) of actin/normalized TβRI levels. Expression of Smurf2WT reduced the abundance of TβRI, whereas expression of Smurf2KdR failed to efficiently reduce the level of TβRI (ANOVA, *Po0.05, ***Po0.001). (b) Lysates of 293T cells transfected with an expression plasmid encoding an HA-tagged constitutively active TβRI in which Threonine 204 is converted to Aspartate (TβRI (TD)) or the control vector together with MYC-tagged Smurf2WTor Smurf2KdR expressing, or their control vector were subjected to Smurf2 immunoprecipitation (α-MYC IP) followed by TβRI (α-HA) and Smurf2 (α-MYC) immunoblotting. Expression of TβRI(TD) was confirmed by immunoblotting. (c) Lysates of cells transfected with a plasmid encoding MYC-tagged Smurf2WTor Smurf2KdR, alone or together with HA-tagged Smad7, or the empty vector were subjected to Smurf2 (α-MYC), Smad7 (α-HA), and actin immunoblotting, the latter serving as the loading control. Left, representative immunoblot from an experiment that was repeated four independent times. Right, mean ( ± S.E.M., n = 4) of actin/normalized Smurf2 levels. Reduction of Smurf2WT is comparable to the reduction in the level of Smurf2KdR upon coexpression of Smad7 (ANOVA, ***Po0.001). 
Discussion
In this study, we have discovered a function for the ubiquitin ligase Smurf2 in the regulation of EMT. Employing 3D cultures of nontransformed mouse mammary epithelial NMuMG cells, knockdown of Smurf2 promotes whereas overexpression of Smurf2 suppresses the ability of TGFβ to induce disruption of acinar morphogenesis of NMuMG cells. We have also found that Smurf2 undergoes sumoylation at Lysines 26 and 369 catalyzed by the SUMO E2 enzyme Ubc9 and the SUMO E3 ligase PIAS3. In mechanistic studies, we have found that sumoylation promotes the ability of Smurf2 to induce the degradation of TβRI and thereby suppresses TGFβ-induced EMT. These findings advance our understanding of the mechanisms that regulate EMT.
Recent studies have shown that TGFβ-induced EMT is regulated by diverse set of post-translational modifications including phosphorylation and ubiquitination. 53, [58] [59] [60] [61] [62] Phosphorylation of specific serine residues of the transcriptional regulator Twist1 activates EMT and cancer metastasis, Smurf2 suppresses EMT in a SUMO-dependent manner AS Chandhoke et al whereas ubiquitin-mediated degradation of Smads inhibits these processes. 18, 63, 64 In other studies, we have found that sumoylation of the transcriptional regulator SnoN suppresses TGFβ-induced EMT. 40, 65 In view of our new findings that Smurf2 suppresses TGFβ-induced EMT, these studies suggest a pivotal role of sumoylation in the regulation of EMT.
Besides undergoing sumoylation, Smurf2 is autoubiquitinated and consequently degraded by the proteasome. 44 Both sumoylation and ubiquitination target specific lysine residues, raising the question of whether and how sumoylation and ubiquitination of Smurf2 might be coordinated. Notably, in our analyses we found no appreciable differences in the abundance of WT and SUMO loss-of-function Smurf2. Consistently, we have found that conversion of the lysine SUMO acceptor sites to arginine in Smurf2 does not significantly affect Smad7-dependent downregulation of Smurf2. In addition, our findings suggest that the lysine to arginine SUMO sites conversion within Smurf2 does not affect Smurf2 association with its adaptor Smad7, and presumably its cognate E2. These observations suggest that distinct lysine residues within Smurf2 are targeted by the SUMO and ubiquitination pathways.
Our study also reveals a mechanism by which sumoylated Smurf2 suppresses EMT. Sumoylation enhances the ability of Smurf2 to induce the degradation of TβRI, explaining how sumoylated Smurf2 opposes the actions of TGFβ signaling in EMT. In future studies, it will be interesting to determine whether sumoylation regulates the ability of Smurf2 to regulate other pathways besides the canonical TGFβ-Smad signaling pathway to control EMT.
Smurf2 regulates diverse biological processes in mitotic and postmitotic cells besides EMT. Smurf2 promotes senescence in fibroblasts, whereas in the nervous system Smurf2 may induce neuronal differentiation and promote neuronal polarization. [66] [67] [68] Whether sumoylation contributes to biological responses of Smurf2 besides EMT will be important to investigate in future studies.
TGFβ-induced EMT plays an important role in regulating normal tissue morphogenesis during development as well as cancer invasiveness and metastasis in adults. Our findings that Smurf2 suppresses TGFβ-induced EMT in a sumoylationdependent manner raises the fundamental question of whether this novel link regulates normal epithelial tissue morphogenesis and affects invasiveness and metastasis of epithelial tumors.
Materials and Methods
Plasmids. CMV-based mammalian expression plasmids containing cDNA encoding MYC-tagged Smurf2 (MYC/Smurf2), HA/SUMO, HA/Ubc9, TβRI/HA, TβRII/HIS, Smad7, FLAG/Smad2, and FLAG/Smad3 proteins have been previously described. 14, 15, 35, 45 Human Smurf2 (K26R), (K369R), and (KdR) in which Lysines 26 and 369, singly or together, are replaced with arginine were generated using a PCR-based site-directed mutagenesis method. 45, 65 Vectors containing cDNA to express Smurf2C2 or Smurf2HECT domains harboring WT or Lysine 26 to arginine or Lysine 369 to arginine were generated using PCR-based mutagenesis and subcloning approaches (Figures 8e and f) . 69, 70 Expression vectors expressing fusion proteins of Renilla luciferase (Rluc) with WT or KdR Smurf2 were generated by PCR-based amplification and subcloning of the Rluc cDNA upstream of Smurf2 cDNA in CMV-based (pCMV5B) Smurf2-expression vectors. 14, 69, 70, 71 Smurf2 RNAi vectors encoding Smurf2 hairpin RNAs targeting one of two distinct regions in Smurf2 (5′-GGGCCAAATGACAATGATACA-3′ (Smurf2i-1) and 5′-GGGAAGT CAATTACCTTGGAT-3′ (Smurf2i-2)) and enhanced green fluorescent protein (EGFP) under the control of the U6 and CMV promoters were cloned as previously described. 72, 73 RNAi-resistant Smurf2 plasmids Smurf2(r1) and Smurf2(r2) were generated by mutating the Smurf2 cDNA corresponding to the RNAi-1 and RNAi-2 target regions. 70, 73 The plasmids were confirmed by DNA sequence analyses (University of Calgary Core Sequencing Facility, Calgary, AB, Canada). The Smad2 and Smad3 RNAi vectors 74, 75 and the FLAG/SENP1 and FLAG/SENP2 expression plasmids were kind gifts from Dr. Azad Bonni (Washington University School of Medicine St. Louis, MO, USA). To establish NMuMG stable cell lines, a pCaGip vector was employed to generate constructs containing cDNA encoding WT Smurf2 or a SUMO loss-of-function (KdR) Smurf2 protein. A feature of this vector is that the puromycin resistance marker and protein of interest are encoded by a bicistronic transcript containing Internal Ribosomal Entry Site (IRES). 65, 69 Cell lines and transfections. Human kidney epithelial 293T cells were cultured in Dulbecco's modified Eagle's medium with high glucose and L-glutamine (Invitrogen, Burlington, ON, Canada) supplemented with 10% fetal bovine serum (FBS, Invitrogen). The NAMRU mouse mammary gland epithelial cells (NMuMG), purchased from American Type Culture Collection (ATCC, Manassas, VA, USA), were maintained in Dulbecco's modified Eagle's medium with high glucose and L-glutamine, supplemented with 10 mg/ml insulin and 10% fetal bovine serum. The 293T cells were transiently transfected using the calcium phosphate precipitation method, whereas NMuMG cells were transfected using Lipofectamine LTX Plus reagents (Thermo Fisher Scientific, Life Technologies Inc., Burlington, ON, Canada). NMuMG cells were transfected with pCaGip vector control or one encoding Smurf2 WT or Smurf2KdR using Lipofectamine LTX Plus reagents and incubation in 2 μg/ml puromycin. 45, 65, 69 The in vivo sumoylation assays, coimmunoprecipitation and immunoblotting. For in vivo sumoylation assays, cells were lysed in TNTE (50 mM Tris, 150 mM NaCl, and 1 mM EDTA) buffer containing 0.5% Triton X-100 along with protease and phosphatase inhibitors, and 0.1% SDS. 69, 73, 76 In addition, 20 mM NEM isopeptidase inhibitor was included in the lysis buffer where indicated. 45, 65 Cell extracts were collected in 1.75 ml Eppendorf tubes and centrifuged at 14 000 × g for 10 min at 4°C. Supernatants of cell lysates were collected and subjected to mouse Smurf2 (Santa Cruz Biotechnology, Dallas, TX, USA), mouse anti-MYC (Covance, Burlington, ON, Canada), or mouse anti-FLAG (Sigma-Aldrich, St. Louis, MO, USA) immunoprecipitation at 4°C, after saving 10% of the supernatant for protein quantification and protein expression analysis. 14, 77, 78 Immunoprecipitated protein and total protein complexes were resolved by SDS-PAGE, followed by transfer to nitrocellulose membranes, and probing using specific antibodies as previously indicated. 45, 65, 69, 79 For coimmunoprecipitation analyses, cells were lysed in TNTE (50 mM Tris, 150 mM NaCl, and 1 mM EDTA) buffer containing 0.5% Triton X-100 along with protease and phosphatase inhibitors and subjected to immunoprecipitation using mouse anti-HA (Biolegend, Burlington, ON, Canada), rabbit anti-HA (Santa Cruz Biotechnology, Figure 8d ), mouse anti-MYC, or mouse anti-FLAG antibody followed by immunoblotting with specific antibodies as indicated. Cell lysates were subjected to mouse anti-actin (Santa Cruz Biotechnology) and used as loading control.
Three-dimensional NMuMG cell formation assay. The nontransformed mouse mammary epithelial NMuMG cells, transiently or stably expressing the indicated proteins, were trypsinized and prepared for 3D culture. 40 Briefly, 75 μl of ice-cold 30% growth factor-reduced Matrigel solution (3 mg/ml final concentration) in growth medium containing antibiotics and antimitotic agents was added to each well of an 8-well chamber slides (Millipore, Billerica, MA, USA). The chamber slides were kept at 37°C in a 5% CO 2 incubator for 1 h to allow the Matrigel cushions to set. Next, 75 μl of 1.3 × 10 4 cells/ml of trypsinized and resuspended NMuMG cells in 30% growth factor-reduced Matrigel-containing growth medium was layered on top of the Matrigel cushion in each well of the 8-well chambers, and kept in a controlled 5% CO 2 humidified incubator at 37°C. The next day, the 3D cell cultures were incubated in the presence or absence of 100 pM TGFβ for 10 days, replenishing the ligand every 3 days. Differential interference contrast (DIC) images of the live 10-day-old NMuMG cellular acini were obtained using an inverted microscope with a 20X objective lens (Olympus IX70, Olympus Canada Inc., Richmond Hill, ON, Canada). The multicellular structures were then fixed with 4% paraformaldehyde, followed by permeabilization using 0.5% cold Triton X-100 solution and blocking using 5% BSA in phosphate-buffered saline. These acini were subjected to immunocytochemical analyses using a rabbit E-cadherin antibody (Cell Signaling Technology, Whitby, ON, Canada) as the primary antibody and Cy3-conjugated antirabbit IgG (Jackson Lab, Burlington, ON, Canada) as the secondary antibody along with the DNA dye bisbenzimide (Hoechst 33258, Invitrogen) to visualize nuclei. Immunofluorescent images of the multicellular colonies were captured using a fluorescent microscope with a 40 × objective lens (Zeiss Axiovert 200M, Toronto, ON, Canada). Exposure times for E-cadherin and Hoechst-specific signals were kept constant in each experiment. For each condition, 6 to 10 colonies per experiment were assessed. 40 Statistical analyses. All data were subjected to statistical analysis by t-test or ANOVA followed by Student-Newman-Keuls test (InStat, San Diego, CA, USA). Values of Po0.05 were considered statistically significant. *Po0.05, **Po0.01, and ***Po0.001. Data were presented graphically as mean ± S.E.M. from experiments that were repeated at least three independent times.
